Schrodinger, Inc. (SDGR)

Schrodinger is a software company that sells computational-chemistry tools to pharmaceutical companies, biotech firms, and materials scientists. The company does not discover drugs itself; instead, it builds the computational platform and simulation software that lets others accelerate drug discovery and optimize molecular structures. Think of it this way: a medicinal chemist at Pfizer used to spend months testing thousands of molecules in the laboratory to find one with the right properties. With Schrodinger’s software, that chemist can simulate thousands of molecules computationally, rank them by predicted efficacy and safety, and focus lab work on the most promising candidates. That saves time, money, and lives — and Schrodinger makes money by licensing its software and charging subscription fees for the use of its platform.

What does Schrodinger actually sell?

Schrodinger’s core product is a suite of computational-chemistry software — tools that simulate how molecules behave, predict their properties, and help researchers design better compounds. The platform includes modules for molecular dynamics (simulating how molecules move and interact), structure-based drug design (docking molecules to protein targets), free-energy calculations (predicting binding affinity), and machine-learning models trained on chemical data. In recent years, Schrodinger has integrated artificial intelligence and neural networks into its platform, so that researchers can feed in chemical and biological data and the software learns patterns that predict which molecules will work best for a given target. This is a powerful time-saver: instead of having a chemist manually design molecules based on intuition and trial-and-error, the algorithm can suggest promising candidates.

Schrodinger licenses this platform to customers on a subscription basis — usually annual contracts that renew if customers continue to find the tool valuable. The largest customers are big pharmaceutical companies (Johnson & Johnson, Merck, Novartis, others) and specialized biotech firms focused on drug discovery. Smaller customers are academic research groups and chemical companies looking to optimize materials. Schrodinger also sells consulting services — its scientists work with a customer’s team to apply the platform to a specific problem, which builds expertise on both sides and strengthens the customer relationship.

How does Schrodinger compete?

The software market for drug discovery is competitive but not crowded. Schrodinger’s main competitors are other computational-chemistry platforms (some built in-house by large pharma companies, others sold by rivals like Schrödinger alternatives). The key competitive advantage is accuracy: if Schrodinger’s software predicts molecular properties better than competitors’ software, pharma companies will pay for it. Accuracy comes from the quality of the underlying algorithms, the amount and quality of training data, and the breadth of chemical space the software has been validated on. Schrodinger has been building this for three decades, so it has a deep library of experimental data to train models on, a track record of performance, and customer loyalty.

Another advantage is integration. Schrodinger’s platform connects to other tools that drug chemists use — molecular databases, lab-information systems, experimental platforms — so it fits into existing workflows rather than forcing researchers to adopt a wholly new way of working. That integration and workflow fit is a powerful moat because switching costs are real. Retraining a team of chemists on a new platform takes time and money.

The risk is that competitors (especially AI-focused companies or well-funded biotech startups) develop superior machine-learning models or integrate artificial intelligence more effectively. If a competitor’s software delivers materially better predictions and faster time-to-discovery, it can poach customers. Schrodinger is investing heavily in AI and machine learning to stay ahead, but it is a crowded space, and no advantage is permanent.

How does Schrodinger make money and spend it?

Revenue comes from software licensing (the bulk) and services. Most customers sign annual contracts, so revenue is somewhat predictable and recurring. The gross margin on software is very high — once the software is built, each additional user license costs almost nothing to deliver. This means Schrodinger’s business has strong leverage: as revenue grows, operating expenses do not grow proportionally, and profitability expands.

However, Schrodinger is not yet profitable on a generally accepted accounting principles (GAAP) basis. The company is investing heavily in research and development (building more features, training better AI models), sales and marketing (selling the platform to new customers), and general operations. These investments are essential to maintain the competitive position and drive growth, but they exceed current revenues. The company is therefore burning cash and relying on its public-market funding to finance the path to profitability.

This is typical for a growth-stage software company. Schrodinger went public in 2020 at a high valuation (the stock opened at a meaningful premium to the IPO price, reflecting investor enthusiasm for the AI and drug-discovery narrative). Since then, the stock has been volatile — rising sharply in periods when AI enthusiasm is high and when biotech is in favor, and falling sharply when the growth-versus-profitability math becomes the focus. Investors are essentially betting that Schrodinger can scale revenue fast enough that the company reaches cash-flow breakeven and then sustained profitability without diluting shareholders further or raising too much capital.

Why pharma companies buy this

Drug discovery is expensive and slow. A pharmaceutical company typically spends one to two billion dollars and ten to fifteen years to bring a single drug from laboratory to market approval. Anything that accelerates that timeline or reduces the failure rate saves enormous sums. Schrodinger’s software does both: it helps researchers identify promising compounds faster, reducing the time and cost of discovery and early development. If Schrodinger can shave even a few months off that timeline or increase the probability of a molecule’s success in the clinic, the value to the pharma customer is measured in tens or hundreds of millions of dollars. The annual subscription fee for Schrodinger’s platform (likely in the millions of dollars for a large pharma customer) is a rounding error against that value, making it an easy buy for the customer.

The trend also favors Schrodinger: as drug targets become more complex (targeting proteins inside cells, precision medicine for rare mutations, immunology), the problem-solving requires better computational tools. Simple guessing-and-testing becomes less viable, so computational power becomes more essential. This tailwind is likely to persist for years.

What to watch

For investors, the key question is whether Schrodinger can grow revenue fast enough to reach sustainable profitability before the company runs out of cash or has to dilute shareholders further. Watch the quarterly revenue growth rate — if it is decelerating significantly, that is a warning sign. Track customer concentration; if the company is overly dependent on a handful of pharma companies, the loss of any single customer is a major setback. Monitor the company’s cash burn and cash balance; a well-funded private company can burn cash indefinitely, but a public company is under pressure to reach cash-flow positive within a reasonable timeframe.

Also pay attention to competitive moves: if larger software vendors (like Moderna Therapeutics, Cambridge HealthTech Institute, or established ERP vendors) begin offering competing computational-chemistry capabilities, Schrodinger faces disruption. And track adoption of the platform by emerging biotech companies; if only large pharma companies use it, the addressable market is limited. If Schrodinger is becoming the standard tool for biotech drug discovery, the company has a durable, large-scale business.

Schrodinger’s long-term value hinges on the fundamentals: software quality, customer concentration, growth trajectory, path to profitability, and competitive durability. The company has a good technical product and a large, enduring market need, but profitability remains unproven. It is a speculative investment suitable for those with conviction in the AI-and-drug-discovery thesis and tolerance for volatility.